{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:26:37Z","timestamp":1777487197434,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-022-02412-x","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T07:20:25Z","timestamp":1675149625000},"page":"1530-1545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct03233126","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04308096","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Takuo","family":"Kubota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Muroya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"issue":"3","key":"2412_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009;160(3):491\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2412_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol. 2016;174(2):125\u201336.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2412_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):58.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2412_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa151","volume":"4","author":"K Dahir","year":"2020","unstructured":"Dahir K, Roberts MS, Krolczyk S, Simmons JH. X-linked hypophosphatemia: a new era in management. J Endocr Soc. 2020;4(12): bvaa151.","journal-title":"J Endocr Soc"},{"issue":"2","key":"2412_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","volume":"22","author":"V Saraff","year":"2020","unstructured":"Saraff V, Nadar R, H\u00f6gler W. New developments in the treatment of X-linked hypophosphataemia: implications for clinical management. Paediatr Drugs. 2020;22(2):113\u201321.","journal-title":"Paediatr Drugs"},{"issue":"7","key":"2412_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321\u201334.","journal-title":"J Endocr Soc"},{"issue":"2","key":"2412_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","volume":"37","author":"N Ferizovi\u0107","year":"2020","unstructured":"Ferizovi\u0107 N, Marshall J, Williams AE, et al. Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal. Adv Ther. 2020;37(2):770\u201384.","journal-title":"Adv Ther"},{"issue":"1","key":"2412_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int. 2021;32(1):7\u201322.","journal-title":"Osteoporos Int"},{"issue":"6","key":"2412_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","volume":"86","author":"AS Lambert","year":"2019","unstructured":"Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A. X-linked hypophosphatemia: management and treatment prospects. Joint Bone Spine. 2019;86(6):731\u20138.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"2412_CR10","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13-30.","journal-title":"Endocr Connect"},{"issue":"8","key":"2412_CR11","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Doria A, Kooh SW, et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003;88(8):3591\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2412_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M BiosseDuplan","year":"2017","unstructured":"BiosseDuplan M, Coyac BR, Bardet C, et al. Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia. J Dent Res. 2017;96(4):388\u201395.","journal-title":"J Dent Res"},{"issue":"10","key":"2412_CR13","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J, Olear EA, Insogna KL, et al. Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab. 2015;100(10):3625\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2412_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"2412_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","volume":"23","author":"Y Yamazaki","year":"2008","unstructured":"Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509\u201318.","journal-title":"J Bone Miner Res"},{"key":"2412_CR16","unstructured":"Kyowa Kirin Limited. CRYSVITA (burosumab). Summary of product characteristics."},{"issue":"10189","key":"2412_CR17","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416\u201327.","journal-title":"Lancet"},{"issue":"3","key":"2412_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271\u201384.","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2412_CR19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res. 2019;34(12):2183\u201391.","journal-title":"J Bone Miner Res"},{"key":"2412_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH, et al. Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int. 2021;108:622\u201333.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2412_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN. Burosumab: first global approval. Drugs. 2018;78(6):707\u201314.","journal-title":"Drugs"},{"key":"2412_CR22","unstructured":"PMDA. New drugs approved in FY 2019. https:\/\/www.pmda.go.jp\/files\/000235289.pdf. Accessed December 2022."},{"key":"2412_CR23","unstructured":"Kyowa Kirin Announces Crysvita\u00ae now reimbursed for self-injection in Japan. December 2020. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2020\/e20201204_01.html. Accessed December 2022."},{"key":"2412_CR24","unstructured":"PharmaTimes. EU approval for self-administered Crysvita. http:\/\/www.pharmatimes.com\/news\/eu_approval_for_self-administered_crysvita_1373330. Accessed December 2022."},{"issue":"Suppl 1","key":"2412_CR25","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.2337\/diacare.27.2007.S106","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association. Insulin administration. Diabetes Care. 2004;27(Suppl 1):S106\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"2412_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113912","volume":"9","author":"SJ Richardson","year":"2014","unstructured":"Richardson SJ, Brooks HL, Bramley G, Coleman JJ. Evaluating the effectiveness of self-administration of medication (SAM) schemes in the hospital setting: a systematic review of the literature. PLoS\u00a0One. 2014;9(12): e113912.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"2412_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJF van den Bemt","year":"2019","unstructured":"van den Bemt BJF, Gettings L, Doma\u0144ska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384\u201392.","journal-title":"Drug Deliv"},{"issue":"5","key":"2412_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2217\/ijr.15.39","volume":"10","author":"MF Marengo","year":"2015","unstructured":"Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol. 2015;10(5):345\u201356.","journal-title":"Int J Clin Rheumtol"},{"issue":"2","key":"2412_CR29","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.18549\/PharmPract.2020.2.1766","volume":"18","author":"R Kaday","year":"2020","unstructured":"Kaday R, Ratanajamit C. Inpatient self-administered medication under the supervision of a multidisciplinary team: a randomized, controlled, blinded parallel trial. Pharm Pract (Granada). 2020;18(2):1766.","journal-title":"Pharm Pract (Granada)"},{"issue":"1","key":"2412_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13023-020-01513-6","volume":"15","author":"E Brizola","year":"2020","unstructured":"Brizola E, Adami G, Baroncelli GI, et al. Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic. Orphanet J Rare Dis. 2020;15(1):228.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2412_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care. 2008;6(1):1\u201314.","journal-title":"Musculoskelet Care"},{"key":"2412_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40814-020-00665-3","volume":"6","author":"CA S\u00f8rensen","year":"2020","unstructured":"S\u00f8rensen CA, Olesen C, Lisby M, Enemark U, de Thurah A. Self-administration of medication during hospitalization-a randomized pilot study. Pilot Feasibility Stud. 2020;6:116.","journal-title":"Pilot Feasibility Stud"},{"issue":"12","key":"2412_CR33","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1007\/s00520-016-3363-3","volume":"24","author":"M Touati","year":"2016","unstructured":"Touati M, Lamarsalle L, Moreau S, et al. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home. Support Care Cancer. 2016;24(12):5007\u201314.","journal-title":"Support Care Cancer"},{"issue":"4","key":"2412_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1017\/S0266462305050701","volume":"21","author":"RA Elliott","year":"2005","unstructured":"Elliott RA, Thornton J, Webb AK, Dodd M, Tully MP. Comparing costs of home- versus hospital-based treatment of infections in adults in a specialist cystic fibrosis center. Int J Technol Assess Health Care. 2005;21(4):506\u201310.","journal-title":"Int J Technol Assess Health Care"},{"key":"2412_CR35","unstructured":"Kamenicky P, Briot K, Brandi ML, et al. Maintenance of effect of burosumab treatment and the impact of treatment interruption across a 96-week phase 3 study and 48 weeks of a phase 3b study in adults with X-linked hypophosphatemia (XLH). Presented at the World Congress on Osteoporosis, Osteoarthritic and Musculoskeletal Disease. Abstract OC9; 2021."},{"issue":"3","key":"2412_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"HD Ochs","year":"2006","unstructured":"Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265\u201373.","journal-title":"J Clin Immunol"},{"issue":"6","key":"2412_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ajh.25776","volume":"95","author":"DJ Kuter","year":"2020","unstructured":"Kuter DJ, Arnold DM, Rodeghiero F, et al. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: results of an integrated database of five clinical trials. Am J Hematol. 2020;95(6):643\u201351.","journal-title":"Am J Hematol"},{"issue":"5","key":"2412_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvac021","volume":"6","author":"N Namba","year":"2022","unstructured":"Namba N, Kubota T, Muroya K, et al. Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3\/4 open-label trial. J Endocr Soc. 2022;6(5):1\u201310.","journal-title":"J Endocr Soc"},{"issue":"8","key":"2412_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383\u201393.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2412_CR40","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s12325-020-01257-6","volume":"37","author":"K Bailey","year":"2020","unstructured":"Bailey K, Mountian I, Bruggraber R, Sunderland K, Tilt N, Szegvari B. Patient satisfaction with CIMZIA\u00ae (certolizumab pegol) AutoClicks\u00ae in the UK. Adv Ther. 2020;37(4):1522\u201335.","journal-title":"Adv Ther"},{"issue":"2","key":"2412_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40744-017-0080-4","volume":"4","author":"M Schiff","year":"2017","unstructured":"Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4(2):445\u201363.","journal-title":"Rheumatol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02412-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02412-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02412-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:41:30Z","timestamp":1680518490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02412-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2412"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02412-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}